- 2 in every 3 patients are on a 6-month or longer treatment-free interval at Year 1 in each of the 3 major retinal vascular diseases, wAMD, DME and RVO, after only 3 loading doses
- 78% of patients with wAMD, 84% with DME and 75% with RVO are on a 4-month or longer treatment interval at Year 1
- Strong anti-VEGF efficacy and encouraging safety profile continue to be observed across all three diseases
- Mean of 2.0, 1.0, and 1.7 retreatments administered in the ten months following the loading phase in wet AMD, DME and RVO patients, respectively
PR Newswire
PALO ALTO, Calif., Feb. 13, 2021